Skip to main content
. 2020 Jun 10;1(1):82–95. doi: 10.1158/2643-3230.BCD-19-0080

Figure 5.

Figure 5. Sensitivity of BCP ALL cells to inhibitors of pre-BCR signaling. A, Ten cell lines (four pre-BCR-negative ALL, three pre-BCR-positive non-MEF2D-ALL, and three MEF2D-ALL lines) were exposed to indicated inhibitors and their sensitivity with respect to growth inhibition was tested. Cells were treated with varying concentrations of the inhibitors as indicated for 3 days. Cell growth is shown relative to that of vehicle-treated control cells (means ± SDs; n = 3). B, Two clinical MEF2D-ALL cell lines were analyzed as in A. C, Immunodeficient mice were transplanted with Kasumi-7 cells engineered to express luciferase, which was monitored by bioluminescence imaging (left). Ibrutinib, dasatinib, and vehicle controls were administered daily from day 1 to day 35 days after transplantation. The survival outcomes were also estimated using the log-rank test (right). Both drugs reduced the leukemia burden and significantly prolonged the survival duration (n = 5 for ibrutinib treatment, otherwise n = 4).

Sensitivity of BCP ALL cells to inhibitors of pre-BCR signaling. A, Ten cell lines (four pre-BCR-negative ALL, three pre-BCR-positive non-MEF2D-ALL, and three MEF2D-ALL lines) were exposed to indicated inhibitors and their sensitivity with respect to growth inhibition was tested. Cells were treated with varying concentrations of the inhibitors as indicated for 3 days. Cell growth is shown relative to that of vehicle-treated control cells (means ± SDs; n = 3). B, Two clinical MEF2D-ALL cell lines were analyzed as in A. C, Immunodeficient mice were transplanted with Kasumi-7 cells engineered to express luciferase, which was monitored by bioluminescence imaging (left). Ibrutinib, dasatinib, and vehicle controls were administered daily from day 1 to day 35 days after transplantation. The survival outcomes were also estimated using the log-rank test (right). Both drugs reduced the leukemia burden and significantly prolonged the survival duration (n = 5 for ibrutinib treatment, otherwise n = 4).